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Background. The fibroblast growth factor (FGF) family has
functions in development, cell proliferation, migration, and dif-
ferentiation. While FGF-2 induces fibrosis, the role of FGF-1
in inflammation and fibrosis is less defined. We examined the
expression of FGF-1 and FGF receptor (FGFR-1) to determine
if renal diseases with varying etiologies of inflammation, includ-
ing lupus nephritis (LN), acute interstitial nephritis (AIN) and
acute rejection superimposed on chronic allograft nephropa-
thy (CAN), showed varying patterns of expression. We also
examined the expression of fibroblast-specific protein-1 (FSP-
1), which has been linked to epithelial-mesenchymal transition
(EMT) and fibrosis, to determine whether it was linked to po-
tential profibrotic and inflammatory FGF-1 mechanisms.
Methods. Proliferative LN (PLN) (N = 12), nonproliferative
lupus nephritis (NPLN) (N = 5), AIN (N = 6), CAN (N =
4), and normal kidneys (N = 3) were studied. FGF, FGFR-1,
and FSP-1 were localized by immunohistochemistry, and inten-
sity scored on a 0 to 3+ scale. Double staining with CD68 and
separate immunohistochemical staining for CD4 and CD8 with
serial sections analysis were done to identify if T lymphocytes or
macrophages showed staining for FGF-1 and FGFR-1 or FSP-1.
Results. In normal kidneys, FGF-1 was expressed in mesan-
gial cells (0.67 ± 0.58), glomerular endothelial (0.67 ± 0.58), vis-
ceral, and parietal epithelial cells (1.67 ± 0.58). FGFR-1 showed
a similar pattern of staining but also was expressed in tubular
epithelium, and arterial endothelium and smooth muscle. Ex-
pression of FGF-1 was increased over normal in glomerular
parenchymal cells only in CAN in podocytes (2.30 ± 0.58 vs.
3.00 ± 0.00) (P < 0.05) and parietal epithelial cells (1.67 ± 0.58
vs. 2.25 ± 0.50) (P < 0.05). Infiltrating glomerular and inter-
stitial inflammatory cells in diseased glomeruli also expressed
FGF-1 and FGFR-1. Tubular cells expressed slightly increased
FGFR-1 in renal diseases vs. normal, whereas tubules remained
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negative for FGF-1 in diseased kidneys. FSP-1 expression was
prominent in the interstitium in all kidneys with interstitial in-
flammation, and most prominent in CAN. Interstitial FSP-1+
cells were consistent with a myofibroblast-type morphology, and
did not stain with CD-68. FSP-1 expression was closely associ-
ated with inflammatory cells expressing FGF-1 and FGFR-1.
FSP-1 also showed positivity within crescents and occasional
podocytes in PLN.
Conclusion. The expression of FGF-1 and FGFR-1 in in-
filtrating lymphocytes and macrophages, and of FGFR-1 in
tubules, is supportive, but does not prove causality, of the pos-
sibility that FGF-1 might have both autocrine and paracrine
functions in renal inflammation. However, the initial stimulus
for renal inflammation, whether immune complex, hypersensi-
tivity or rejection, did not alter expression patterns of FGF-1 or
its receptor. The colocalization of inflammatory infiltrates with
interstitial fibrosis supports the possibility of a contribution of
FGF-1 for chemotaxis and associated fibrosis, further supported
by interstitial FSP-1 expression closely associated with these in-
flammatory cells expressing FGF-1 and FGFR-1.
Progressive renal disease, regardless of the initiating
insult, is characterized by glomerulosclerosis, tubuloint-
erstitial fibrosis, and vascular sclerosis. Numerous factors,
including growth factors, chemokines, cytokines, and re-
active oxygen species, have been implicated in the pro-
cess of progressive renal scarring. Tubular epithelial cells
contribute to this process by changing their phenotype
with expression of a fibroblast-specific protein-1 (FSP-1),
and migrating into the interstitium, so-called epithelial-
mesenchymal transition (EMT) [1, 2].
The fibroblast growth factor (FGF) family includes at
least 23 heparin-binding proteins with different biologic
functions in developmental and repair processes of tis-
sues [3]. FGFs act through binding to high-affinity tyro-
sine kinase receptors (FGFR) encoded by four genes that
by alternative mRNA splicing can generate seven func-
tional FGFR variants [4]. During embryonic develop-
ment, FGF/FGFR signals play a major role in mesoderm
organization, body axis and neural axis formation, and
tissue/organ induction [5–7].
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While some FGF members such as FGF-2 [basic FGF
(bFGF)] have been proven to play a role in the pathogen-
esis of renal disease by inducing fibrosis and contributing
to renal damage in immune-mediated injury [8–10], the
role of FGF-1 [acidic FGF (aFGF)] in renal disease is
less defined. FGF-1 may play a role in inflammatory dis-
ease such as rheumatoid arthritis. FGF-1 expression was
increased in synovial cells of patients with rheumatoid
arthritis and enhanced expression of its receptor (FGFR-
1) was found in perivascular CD4+ T lymphocytes at sites
of injury. Furthermore, T cells activated by FGF-1 were
also increased in the peripheral blood of these patients
[11]. Transforming growth factor-b (TGF-b) increased
FGF-1 production by cultured synovial cells [12].
FGF-1 may also play a role in the fibrotic response to
tissue injury. FGF-1 and FGFR are actively synthesized
during the development of pulmonary fibrosis induced
in rats with paraquat plus hyperoxia [13]. The entry of
fibroblasts into the interstitium and the process of EMT
require initial degradation of matrix. FSP-1 is a marker
of EMT. FGF-1 promotes collagenase and urokinase-
like plasminogen activator receptor (u-PAR) production,
both of which promote these processes. Expression of
FSP-1 and FGF-1 therefore could be linked, reflecting
a potential interrelationship in inflammation, EMT, and
fibrosis.
Several studies have evaluated the localization of
FGF-1 and its receptor FGFR-1 in the normal kidney,
both in experimental models and in humans. Ichimura
et al [14] observed expression of FGF-1 in distal tubule
elements, as well as in blood vessel and glomeruli of adult
rats. Also in rats, Cancilla et al [15] observed expres-
sion of FGFR-1 in glomeruli, thin limbs, distal straight
tubules, distal convoluted tubules, medullary collecting
ducts, and smooth muscle of renal arteries. In humans,
Floege et al [16] observed expression of FGFR-1 protein
and mRNA in tubular cells of the distal nephron and in
vascular smooth muscle cells.
However, few studies have explored the role expres-
sion of FGF-1 in renal disease, or even more specifically
in inflammatory/fibrotic renal diseases. Ichimura et al [14]
showed that FGF-1 may play an autocrine and paracrine
role in the regenerative changes observed in the rat prox-
imal tubular epithelium following administration of S-
(1,1,2,2,-tetrafluoroethyl)-L-cysteine, In vascular lesions
of kidney allografts with chronic allograft nephropathy
(CAN), there was increased expression of both FGF-1
protein and mRNA in resident inflammatory and tubu-
lar epithelial cells in tubulointerstitial lesions [17], and
increased expression of FGF-1 and its receptors in vascu-
lar lesions of kidney allografts with CAN [18], suggesting
that FGF-1 may act as an important mediator of growth
and repair responses associated with development
of vascular and tubulointerstitial lesions occurring in
CAN.
Table 1. Clinical findings at time of biopsy/nephrectomy
Systolic Serum
Age blood pressure creatinine Proteinuria
Diagnosis years mm Hg mg/dL g/24 hours
Proliferative
lupus nephritis
27.6 ± 4.4 132.4 ± 5.7 1.6 ± 0.4 4.5 ± 1.7
Nonproliferative
lupus nephritis
20.6 ± 3.0 111.3 ± 4.9 0.9 ± 0.2 2.3 ± 0.7
Acute interstitial
nephritis
43.8 ± 6.5 124.0 ± 13.0 5.1 ± 1.6 0.3 ± 0.2
Chronic allograft
nephropathy
31.3 ± 4.0 N/A 10.1 ± 1.3 N/A
Normal 24.7 ± 8.7 N/A N/A N/A
Data are shown as mean ± SE. N/A is data not available.
We therefore sought to examine the expression of
FGF-1 and its receptor specifically in various inflam-
matory renal diseases with interstitial inflammation, in-
cluding lupus nephritis (LN), acute interstitial nephritis
(AIN), and acute rejection superimposed on CAN, and
examine any linkage to type of inflammatory infiltrate
and fibrosis. We also further examined the colocalization




Formalin-fixed, paraffin-embedded renal tissues from
core needle biopsies in normal control kidneys (N = 4)
proliferative LN (PLN) (N = 12), nonproliferative LN
(NPLN) (N = 5), AIN (N = 6), and from transplant
nephrectomies with acute rejection and CAN (N = 4)
were included in this study after the diagnostic workup
was completed. Clinical data from these patients at re-
nal biopsy are shown in Table 1. Of note, normal tissue
was from patients in whom further clinical records were
unavailable to us due to HIPA regulations. There were
nine women and three men with PLN, four women and
one man with NPLN, three women and two men with
AIN, and two women and two men with CAN. Gender
was known for three normal controls, and included two
women and one man. As expected by clinical indications
for biopsy, patients with AIN and CAN had higher serum
creatinine levels than PLN or NPLN, whereas the lat-
ter had higher levels of proteinuria. Corticosteroid treat-
ment had been given to seven PLN and four each NPLN
and AIN patients. In addition, one NPLN patient had
received cytotoxic therapy. Most LN patients had re-
ceived nonsteroidal anti-inflammatory drugs, nine PLN
and three NPLN. All transplant patients were on various
immunosuppressive drugs, including corticosteroids in all
and calcineurin inhibitors in most.
Normal control kidneys showed no evidence of abnor-
malities by light, immunofluorescence, and electron mi-
croscopy. The PLN group was composed of seven patients
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with World Health Organization (WHO) class IV [In-
ternational Society of Nephrology/Renal Pathology So-
ciety (ISN/RPS) IV S (A), one; S (A/C), three; and G
(A/C), three] and five with WHO class III (ISN/RPS III
A, two; and A/C, three) LN [19]. Three of class IV and
two of class III cases had crescents. All PLN cases had
increased intraglomerular leukocytes and interstitial in-
filtrates. The NPLN group was composed of two patient
with WHO class II (ISN/RPS II) and three with WHO
class V (ISN/RPS V) LN. All these latter biopsies had less
interstitial inflammatory infiltrates and few intraglomeru-
lar leukocytes compared to the PLN group. All biopsies in
the AIN group showed significant interstitial eosinophils.
Therefore, drug-induced hypersensitivity was thought to
represent the most likely underlying etiology. Only a few
intraglomerular leukocytes were observed in this group.
All cases in the CAN group were transplant nephrectomy
specimens removed due to pain. All these CAN cases also
had superimposed acute vascular and cellular rejection,
type 1 and type 2, according to Cooperative Clinical Trials
in Transplantation (CCTT) criteria [20].
Immunohistochemistry
FGF-1, FGFR-1, and FSP-1. Thin sections (2 lm) of
the renal biopsies were deparaffinized and dehydrated
by a series of xylene and alcohol washes. Following
quenching of endogenous peroxidase activity with 3%
(vol/vol) H2O2 in methanol × 10 minutes, sections were
microwaved (20 minutes) in citrate buffer for antigen re-
trieval. The tissues were blocked with 1% (wt/vol) bovine
serum albumin (BSA) and incubated with polyclonal
antibodies directed against FGF-1 (1:100) (Sigma-
Aldrich, St. Louis, MO, USA) or FGFR-1 (1:200) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), directed at
the high-affinity signaling isoform with active kinase do-
main, thus detecting functional receptors, for 90 minutes
at room temperature, or against FSP-1 (polyclonal rabbit
anti-FSP-1) (1:200), at 37◦C for 1 hour in a humidified
chamber [1]. This specificity was further verified by us-
ing an FGF-Ig fusion protein to first immunoprecipitate
FGFR-1 and then blot with the anti-FGFR-1 reagent [21].
In addition, monoclonal antibodies directed at the first
Ig loop of FGFR-1 and inhibition with a FGFR-1 specific
peptide also confirmed the specificity of the anti-FGFR-1
reagent (unpublished observations). Using recombinant
FGF-1, the anti-FGF-1 reagent is highly specific for FGF-
1 on Western blot, and, importantly, does not cross-react
with FGF-2 (bFGF), FGF-5, or FGF-7 [11, 12]. Positive
control included synovial tissue with known FGF-1 and
FGFR-1 expression by Western blot, and fibrotic kid-
neys with FSP-1 expression. Negative controls for all an-
tibodies included incubation of sections with preimmune
serum and deletion of the primary antibody, a process
that completely prevented immunostaining. Secondary
antibody was added (goat antirabbit (1:50) (Southern
Biotechnology Associates, Birmingham, AL, USA) and
incubated for 30 minutes. Peroxidase-stained sections
were then developed with 3,3′-diaminobenzidine (DAB)
and counterstained with hematoxylin (Sigma-Aldrich).
Double staining with CD68 and separate stainings for
CD4 and CD8 with serial sections analysis were done to
identify if any macrophages or T lymphocytes showed
staining for FGF-1 and FGFR-1 as follows.
CD68. Sections stained with FGF-1, FGFR-1, and
FSP-1 as above were double stained with antibod-
ies against macrophages. Powerblock (BioGenex, San
Ramon, CA, USA) diluted 1:10 with PBS Triton (Sigma-
Aldrich) was used to block remaining endogenous
peroxidase activity. The slides were then incubated
with antibodies against CD68 (1:100) (Sigma-Aldrich)
at room temperature for 90 minutes. Antibody bind-
ing was detected by incubating with prediluted sec-
ondary antimouse (BioGenex) for 30 minutes followed
by streptavidin-conjugated alkaline phosphatase (Bio-
Genex) for 30 minutes. Peroxidase-stained sections were
developed with Fast Red chromogen (Sigma-Aldrich).
Following chromagen development, slides were cover-
slipped using aqueous-based mounting media. Tissue
from tonsil was used a positive control.
CD4 and CD8. Additional serial sections were stained
separately with antibodies against CD4 and CD8 (1:20)
(Novocastra, Newcastle upon Tyne, UK). Endogenous
peroxidase activity was exhausted with 0.5% (vol/vol)
H2O2. For CD4 antigen retrieval, slides were immersed
in buffer solution, placed in pressure cooker, and mi-
crowaved for 15 minutes. For CD8, slides were immersed
in buffer solution and microwaved for 20 minutes. Pri-
mary antibodies were then added for 60 minutes, an-
timouse antibody (Ready to Use) (BioGenex) applied
for 30 minutes followed by horseradish peroxidase–
conjugated streptavidin for 15 minutes. The chromogen
reaction was developed with DAB and the slides were
counterstained with hematoxylin.
Staining scoring. Immunostaining for FGF-1, FGFR-
1, CD4, CD8, and CD68 was evaluated by light mi-
croscopy in a blinded fashion. The intensity of each
glomerular cell type staining was scored on a 0 to 3+ scale:
0, no staining identified; 1+, less than 25% of glomerular
cells positive; 2+, 25% to 75% of glomerular cells posi-
tive; and 3+, more than 75% of glomerular cells positive.
Resident glomerular cells were identified by morphology
and anatomic location, as double staining could techni-
cally not be performed due to different pH requirements
for each of the antibodies. Macrophages were identified
by positivity for CD68. Expression of FGF-1, FGFR-
1, and FSP-1 was evaluated by double immunostaining
technique for CD68. FSP-1 staining was qualitatively
assessed, and identification of staining in CD68-negative
cells done by morphologic assessment. CD4 and CD8+
T cells were identified by staining and their expression
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Fig. 1. Fibroblast growth factor-1 (FGF-1) expression was moderately
increased in podocytes and parietal epithelial cells in occasional dis-
eased kidneys, as seen here in chronic allograft nephropathy (CAN)
(anti-FGF-1 antibody, 400×).
of FGF-1 and FGFR-1 was evaluated by comparison
between consecutive serial sections. Tubular, interstitial,
and vascular stainings were semiquantitatively evaluated
on a scale from 0 to 3+ (0, absent staining; 1+, moder-
ately strong staining in less than 25% of cells; 2+, strong
staining in 25% to 50% of the cells; and 3+, very strong
staining in >50% of cells).
Statistical analysis
Results are expressed as mean ± standard deviation
(SD). Statistical difference was assessed by analysis of
variance (ANOVA) followed by t test or Mann-Whitney
U for nonparametric data as appropriate. A P value <0.05
was considered to be significant.
RESULTS
Glomeruli
Immunohistochemical analysis in normal control kid-
neys showed localization of FGF-1 in mesangial cells
(0.67 ± 0.58), glomerular endothelial cells (0.67 ± 0.58),
podocytes (2.30 ± 0.58), and parietal epithelial cells
Fig. 2. Infiltrating inflammatory cells, identified as macrophages by
double staining (red) in glomerulus of proliferative lupus nephritis, also
showed expression of fibroblast growth factor-1 (FGF-1) (brown) (A)
and FGF receptor-1 (FGFR-1) (brown) (B) [anti-FGF-1 + CD68 anti-
bodies (A), anti-FGFR-1+ CD68 antibodies (B), both 400×].
(1.67 ± 0.58). FGFR-1 showed a similar localization pat-
tern of staining (mesangial cells 1.33 ± 0.58; glomerular
epithelial cells 1.33 ± 0.58; podocytes 2.33 ± 0.58; and
parietal epithelial cells 2.33 ± 0.58) (Table 2). FGF-1 ex-
pression in parenchymal cells in diseased kidneys was sig-
nificantly increased compared to normal controls only in
podocytes (2.30 ± 0.58 vs. 3.00 ± 0.00) (P < 0.05) and pari-
etal epithelial cells (1.67 ± 0.58 vs. 2.25 ± 0.50) (P < 0.05)
in CAN (Fig. 1). Other glomerular parenchymal cells of
diseased kidneys showed no significant change in the ex-
pression of FGF-1 or FGFR-1 compared to normals.
Diseased glomeruli, especially those from PLN, had
increased intraglomerular infiltrating inflammatory cells
(mostly macrophages) expressing FGF-1 and FGFR-
1 (Fig. 2). The localization of FGF-1 and FGFR-1 in
macrophages and T lymphocytes was confirmed by dou-
ble staining for CD68, and by serial sections analysis with
separate staining for CD4 and CD8.
FSP-1 was localized within organizing crescents and
occasional podocytes in PLN (Fig. 3). Double staining
revealed that FSP-1+ cells did not stain with CD68.
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Table 2. FGF-1 and FGFR-1 expression in glomerular parenchymal
cells
FGF-1 FGFR-1
Cell type Groups (Mean ± SD) (Mean ± SD)
Mesangial cell AIN 1.20 ± 0.83 2.20 ± 1.09
CAN 1.50 ± 0.58 1.00 ± 0.81
PLN 1.29 ± 1.10 1.67 ± 1.15
NPLN 1.60 ± 1.14 1.40 ± 1.14
Normal 0.67 ± 0.58 1.33 ± 0.58
Glomerular endothelial cell AIN 1.60 ± 1.34 2.40 ± 0.89
CAN 1.00 ± 0.00 0.50 ± 1.00
PLN 1.08 ± 1.08 1.67 ± 1.15
NPLN 1.40 ± 1.14 1.40 ± 0.89
Normal 0.67 ± 0.58 1.33 ± 0.58
Podocyte AIN 2.40 ± 0.55 2.40 ± 0.89
CAN 3.00 ± 0.00a 1.50 ± 1.29
PLN 2.50 ± 0.80 2.17 ± 0.83
NPLN 2.40 ± 0.89 2.00 ± 1.00
Normal 2.30 ± 0.58 2.33 ± 0.58
Parietal epithelial cell AIN 2.20 ± 0.83 2.60 ± 0.54
CAN 2.25 ± 0.50a 2.00 ± 0.81
PLN 1.90 ± 0.79 2.54 ± 0.52
NPLN 2.20 ± 0.83 2.80 ± 0.44
Normal 1.67 ± 0.58 2.33 ± 0.58
The expression pattern of FGF-1 and its receptor did not change in glomeruli
of diseased kidneys with varying inflammatory processes. There was increased
expression of FGF-1 only in CAN in podocytes and parietal epithelial cells.
aP < 0.05 compared to normal.
Fig. 3. Fibroblast-specific protein-1 (FSP-1) (brown) showed positivity
within crescents (A) and occasional podocytes (B) in proliferative lupus
nephritis (PLN) [anti-FSP-1+ CD68 antibodies, 400× (A) and 200×
(B)].
Fig. 4. Tubular cell expression of fibroblast growth factor receptor-1
(FGFR-1) was slightly increased in diseased kidney, illustrated by pro-
liferative lupus nephritis (PLN) (B) vs. normal (A) (anti-FGFR-1 anti-
body, both 400×].
Tubulointerstitial compartment
In normal kidneys, FGF-1 was not expressed in tubular
epithelial cells. In contrast, FGFR-1 was normally local-
ized in tubular epithelium, and also in arterial endothe-
lium and smooth muscle. In kidneys with inflammatory
conditions, tubular epithelial cells expressed slightly in-
creased FGFR-1 compared to normal controls (Fig. 4),
whereas FGF-1 remained negative in tubules.
Double staining for CD 68 and serial sections analysis
with separate staining for CD4 and CD8 showed that in-
terstitial macrophages, CD4+ and CD8+ T lymphocytes
frequently expressed FGF-1 and FGFR-1 in inflamma-
tory infiltrates of diseased kidneys, most prominently in
PLN, AIN, and CAN with rare positive inflammatory cells
in NPLN (Fig. 5). These inflammatory cell infiltrates were
closely associated with areas of interstitial fibrosis.
FSP-1 expression was prominent in the interstitium
of all kidneys with interstitial inflammation, and most
prominent in CAN (Fig. 6). Occasional atrophic tubules
showed FSP-1 positivity. Interstitial FSP-1+ cells were
consistent with a myofibroblast-type morphology. Dou-
ble staining, again, revealed that FSP-1+ cells did not
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Fig. 5. CD4/CD8 T lymphocytes in interstitium of proliferative lu-
pus nephritis (PLN) kidneys (left panel) also expressed both fibrob-
last growth factor-1 (FGF-1)/FGF receptor-1 (FGFR-1), as did CD68+
macrophages (right panel, serial section of left panel) (all 200×).
stain with CD68. In the interstitium, FSP-1 expres-
sion was closely associated with the presence of fibrosis
and of inflammatory cells (i.e., macrophages, CD4 and
CD8 T lymphocytes) expressing FGF-1 and its receptor
FGFR-1.
DISCUSSION
FGF-1 and FGF-2 are members of a family of heparin-
binding growth factors that stimulate proliferation, mi-
gration, and differentiation of cells of neuroectodermal
and mesodermal origin. FGF-2 has been proven to play a
role in the pathogenesis of renal disease by inducing fibro-
sis and contributing to renal damage in immune-mediated
injury [8–10]. The role of FGF-1 in kidney disease in less
known. FGF-1 is widely expressed during normal embry-
onic development and there is evidence suggesting that
it may also play a role in adult tissues at sites of injury in
different phases of the wound healing process [4].
FGF-1 expression is increased in some immune-
mediated disorders, including rheumatoid arthritis and
cardiac and renal allograft undergoing chronic rejection.
FGF-1 and its receptor FGFR-1 are overexpressed in syn-
ovial cells of patients with rheumatoid arthritis. In addi-
tion, a subset of FGFR-1–bearing CD4+ T-lymphocytes
was found in the blood of these patients [11]. For CD4+ T
cells that express FGFR-1, FGF-1 may provide a costim-
ulatory signal required for interleukin (IL)-2 production
[22, 23]. Increased FGF-1 and FGFR-1 have been found
to correlate with accelerated graft arteriosclerosis (AGA)
in human heart allografts. Further, soluble FGFR-1, ca-
pable of binding both FGF-1 and FGF-2, inhibited AGA
in rats undergoing aortic transplant [24].
The potential role of FGF-1 role in kidney disease has
been explored in only a few studies, mainly in transplants.
Whether this growth factor also could play a role in other
Fig. 6. Fibroblast-specific protein-1 (FSP-1) expression was most
prominent in the interstitium of chronic allograft nephropathy (CAN)
in cells with myofibroblast-like morphology. FSP-1+ cells did not stain
with CD68 [anti-FSP-1+ CD68 antibodies, 200× (A) and 400× (B)].
inflammatory conditions is not known. Previous studies
found increased FGF-1 and FGFR-1 expression in trans-
planted kidneys with CAN in blood vessels and tubuloin-
terstitial compartment compared to controls, particularly
in area of intimal proliferation and inflammation [17, 18].
In the glomeruli, increased of FGF-1 was observed only
in visceral and parietal epithelial cells [25], similar to the
current study. Further, in a murine model of autoimmune
nephritis there was no change in FGF-1 [26].
In the present study, we examined the expression of
FGF-1 and its receptor in various inflammatory renal
diseases, LN, AIN, and acute rejection superimposed on
CAN, and examined whether there was any linkage to
type of inflammatory infiltrate and fibrosis. We found that
renal inflammation, whether immune complex, hypersen-
sitivity or rejection type, did not alter expression patterns
of FGF-1 or its receptor in glomeruli. There was signifi-
cantly increased glomerular parenchymal FGF-1 expres-
sion only in CAN, in visceral and parietal epithelial cells,
confirming previous studies in transplants [25]. We also
observed that infiltrating cells, including macrophages,
CD4- and CD8-positive T lymphocytes, expressed FGF-1
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and its receptor FGFR-1. In the interstitium the in-
flammatory cell infiltrates and corresponding FGF-1 and
FGFR-1 expression were mainly associated with areas of
fibrosis. In addition, compared to normal controls, FGFR-
1 expression was also slightly increased in tubules of dis-
eased kidneys, where FGF-1 remained negative. These
findings suggest the possibility that FGF-1 produced by
inflammatory infiltrating cells might have both autocrine
and paracrine functions in renal inflammation and associ-
ated fibrosis, but do not prove causality of this hypothesis.
These results also confirm the work of others suggesting
that infiltrating cells, a source of FGF-1, might play a role
through their mitogenic properties in tubulointerstitial
remodeling after injury [27, 28].
We also examined FSP-1 expression and any possible
link with the FGF-1/FGFR-1 axis. FSP-1 is a fibroblast-
specific protein and is expressed by tubular epithelial cells
that undergo EMT, a process in which the tubular ep-
ithelial cell changes its phenotype and migrates into the
interstitium where it can participate in the scarring pro-
cess [1]. Our study shows that FGFR-1 was expressed
in the normal tubular epithelium and that its expres-
sion was slightly increased in tubules of diseased kidneys.
We also found that expression of FSP-1 was prominent
in the interstitium of all kidneys with interstitial inflam-
mation, a process often associated with fibrosis. Further,
we found that interstitial FSP-1+ cells did not stain with
CD68, a macrophage marker, and by morphology FSP-1
appeared to be positive in myofibroblast type cells and
not lymphocytes. The interstitial inflammatory cells (i.e.,
macrophages, CD4 and CD8 T lymphocytes) expressed
FGF-1 and its receptor FGFR-1. Of note, increased ex-
pressions of molecules in human renal disease do not
prove causality of these proteins in the disease process.
However, this data support the hypothesis that the FGF-
1/FGFR-1 axis could play a role in the EMT and fibro-
sis evidenced by colocalized FSP-1 expression. Further
specific manipulations in experimental systems are nec-
essary to explore this possibility. These data also support
that FSP-1 is a marker of fibrogenesis in human tissue as
well as in rodents. In addition, FSP-1 also showed positiv-
ity within organizing crescents and occasional podocytes
in PLN, suggesting the hypothesis that not only tubular
cells, but also injured podocytes in inflammatory diseases
may transition to a profibrotic state. Podocyte dediffer-
entiation occurs in a severe glomerular injury seen in
collapsing glomerulopathy or human immunodeficiency
virus (HIV)-associated nephropathy [29]. However, the
expression of FSP-1, a marker of EMT, has not to our
knowledge been documented in podocytes before. FGF-
1 and its receptor FGFR-1 might also play a role in
this process since they are expressed in those glomerular
parenchymal cells. More studies are needed to investigate
this hypothesis and to specifically determine whether the
FGF-1/FGFR-1 axis is linked to the EMT.
CONCLUSION
Our results show that the localization of FGF-1 and
its receptor is not modified in glomerular parenchymal
cells of inflammatory renal disease. However, FGF-1
and FGFR-1 are increased in inflammatory diseases in
macrophages, CD4- and CD8-positive T lymphocytes in-
filtrating both glomeruli and interstitium. In the intersti-
tium FGF-1 and FGFR-1–bearing inflammatory cells are
mainly localized in areas of interstitial fibrosis, in areas
with increased FSP-1. Whether the FGF-1/FGFR-1 axis
also plays a role in EMT in podocytes is a hypothesis
that merits further investigation. FGFR-1, but not FGF-
1, is increased and expressed in tubular epithelial cells
of diseased kidneys. Our data thus suggest that FGF-1
produced by infiltrating inflammatory cells might play an
autocrine and paracrine role in tubulointerstitial remod-
eling and EMT after injury.
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